Ginkgo Bioworks Holdings Inc (NYSE: DNA) kicked off on Tuesday, up 4.72% from the previous trading day, before settling in for the closing price of $7.63. Over the past 52 weeks, DNA has traded in a range of $5.26-$75.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 104.75% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 41.34%. With a float of $35.44 million, this company’s outstanding shares have now reached $38.13 million.
In an organization with 1218 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.77%, operating margin of -406.93%, and the pretax margin is -486.98%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 32.60%, while institutional ownership is 44.83%. The most recent insider transaction that took place on Nov 05 ’24, was worth 745. Before that another transaction happened on Nov 04 ’24, when Company’s Officer proposed sale 1,322 for $7.58, making the entire transaction worth $10,015.
Ginkgo Bioworks Holdings Inc (DNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 41.34% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Take a look at Ginkgo Bioworks Holdings Inc’s (DNA) current performance indicators. Last quarter, stock had a quick ratio of 4.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -18.03, a number that is poised to hit -2.73 in the next quarter and is forecasted to reach -7.55 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.64 million. That was inferior than the volume of 1.13 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.67%. Additionally, its Average True Range was 0.61.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 20.16%, which indicates a significant decrease from 24.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.80% in the past 14 days, which was lower than the 113.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.54, while its 200-day Moving Average is $25.56. However, in the short run, Ginkgo Bioworks Holdings Inc’s stock first resistance to watch stands at $8.17. Second resistance stands at $8.35. The third major resistance level sits at $8.67. If the price goes on to break the first support level at $7.67, it is likely to go to the next support level at $7.35. Assuming the price breaks the second support level, the third support level stands at $7.17.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
The company with the Market Capitalisation of 444.05 million has total of 55,575K Shares Outstanding. Its annual sales at the moment are 251,460 K in contrast with the sum of -892,870 K annual income. Company’s last quarter sales were recorded 56,210 K and last quarter income was -217,180 K.
